Efficacy and Safety of Itepekimab in Patients with Moderate …
Oct 27, 2021 · Itepekimab is a new human IgG4P monoclonal antibody against interleukin-33. The objective of this trial was to evaluate the efficacy and safety of itepekimab treatment, as …
Sanofi and Regeneron’s REGN3500 trial meets primary endpoint
They were given fluticasone / salmeterol as the ICS/LABA maintenance therapy, which was withdrawn during the trial. Regeneron Pharmaceuticals president and chief scientific officer …
Itepekimab (REGN-3500) | IL-33 mAb | MedChemExpress
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has …
Monoclonal antibodies in the management of asthma: Dead ends, …
Itepekimab, found in the literature under the aliases REGN-3500 or SAR440340, is an anti-IL33 antibody that has recently been studied or treating asthma. Although research on this antibody …
Regeneron, Sanofi antibody works in asthma, but not as well as …
Jun 21, 2019 · Dive Brief: Regeneron and Sanofi said Friday their experimental IL-33 antibody improved asthma control better than placebo in a Phase 2 study.; But REGN3500 didn't beat …
Regeneron and Sanofi Announce Positive Topline Phase 2 …
Jun 21, 2019 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 …
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 ...
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in …
Itepekimab Drug Profile - Ozmosi
Alternative Names: Itepekimab, regn-3500, regn3500, regn 3500, sar-440340, sar 440340, sar440340 Latest Update: 2025-04-02 Latest Update Note: Clinical Trial Update. Product …
Mixed results for REGN-3500's phase II asthma trial dent IL-33 …
Jun 24, 2019 · Top-line data for Sanofi SA and Regeneron Pharmaceuticals Inc.'s phase II trial of the IL-33 antibody REGN-3500 show patients with moderate to severe asthma treated with …
Itepekimab (REGN-3500) is a mAb of IL-33 for Inflammation …
Mar 14, 2023 · To sum up, Itepekimab (REGN-3500) is a mAb of IL-33 and can be used for the research of inflammation. Reference: [1] Wechsler ME, et al. N Engl J Med. 2021 Oct …